Tucatinib Continuation Study

StatusNot Yet Recruiting
PhasePhase 4
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Aug 24, 2026 to Nov 6, 2026v2
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Pfizer
441 trials monitored
See 30 trials at risk
Breast Cancer
5,481 trials monitored
See 311 trials at risk
Lung Cancer
4,820 trials monitored
See 267 trials at risk
Colorectal Cancer
3,418 trials monitored
See 162 trials at risk
and 5 more diseases
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.
Trial Details
NCT Number NCT07768358
Lead Sponsor Pfizer
Conditions
(from sponsor)		 HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Related terms Biliary Tract Neoplasms, Colorectal Neoplasms, Uterine Cervical Neoplasms
Enrollment 175 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov